Strategic shift to fully focus on ReNeuron’s Proprietary Exosomes Platform
04 July 2022: ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell derived exosome technologies, announces its preliminary results for the year ended 31 March 2022.
Strategic shift to fully focus on ReNeuron’s Proprietary Exosomes Platform
04 July 2022: ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell derived exosome technologies, announces its preliminary results for the year ended 31 March 2022.